Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice

[1]  P. Finn,et al.  Proteolytic and lipolytic responses to starvation. , 2006, Nutrition.

[2]  R. Schiffelers,et al.  Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[3]  M. Gallicchio,et al.  Substance P‐induced cyclooxygenase‐2 expression in human umbilical vein endothelial cells , 2006, British journal of pharmacology.

[4]  R. Schiffelers,et al.  Therapeutic Application of Long-Circulating Liposomal Glucocorticoids in Auto-Immune Diseases and Cancer , 2006, Journal of liposome research.

[5]  R. Kalluri,et al.  Endogenous inhibitors of angiogenesis. , 2005, Cancer research.

[6]  M. Battaglia,et al.  Platelet Factor 4 Differentially Modulates CD4+CD25+ (Regulatory) versus CD4+CD25− (Nonregulatory) T Cells1 , 2005, The Journal of Immunology.

[7]  R. Schiffelers,et al.  Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice. , 2005, Neoplasia.

[8]  Frieder Keller,et al.  Pharmacokinetics and Pharmacodynamics of Systemically Administered Glucocorticoids , 2005, Clinical Pharmacokinetics.

[9]  D. Ganea,et al.  Prostaglandin E2 Promotes the Survival of Bone Marrow-Derived Dendritic Cells1 , 2004, The Journal of Immunology.

[10]  G. Burmester,et al.  Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. , 2004, Arthritis and rheumatism.

[11]  J. Cidlowski,et al.  Mechanisms of glucocorticoid receptor signaling during inflammation , 2004, Mechanisms of Ageing and Development.

[12]  A. Pfeiffer,et al.  Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. , 2004, European journal of endocrinology.

[13]  R. Kofler,et al.  Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance , 2004, Cell Death and Differentiation.

[14]  P. Farthing,et al.  Stimulation of adhesion molecule expression in human endothelial cells (HUVEC) by adrenomedullin and corticotrophin. , 2004, American journal of physiology. Cell physiology.

[15]  J. Lehoux,et al.  ACTH induces TIMP-1 expression and inhibits collagenase in adrenal cortex cells , 2004, Molecular and Cellular Endocrinology.

[16]  J. Jorcano,et al.  Glucocorticoid Receptor Counteracts Tumorigenic Activity of Akt in Skin through Interference with the Phosphatidylinositol 3-Kinase Signaling Pathway. , 2004, Molecular endocrinology.

[17]  P. Claudio,et al.  Molecular basis of angiogenesis and cancer , 2003, Oncogene.

[18]  M. Gougerot-Pocidalo,et al.  Regulation of Interleukin 12 p40 and p70 Production by Blood and Alveolar Phagocytes During Severe Sepsis , 2003, Laboratory Investigation.

[19]  M. Wauben,et al.  Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. , 2003, Arthritis and rheumatism.

[20]  S. Kiselev,et al.  Molecular Mechanisms of Tumor Angiogenesis , 2003, Biochemistry (Moscow).

[21]  S. Bayramov.  Concentration Oscillations in Three-Component Reaction Systems , 2003, Biochemistry (Moscow).

[22]  R. MacCallum,et al.  Stress-related modulation of matrix metalloproteinase expression , 2002, Journal of Neuroimmunology.

[23]  A. Amsterdam,et al.  Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action. , 2002, Biochemical pharmacology.

[24]  D. Gilroy,et al.  Different glucocorticoids vary in their genomic and non‐genomic mechanism of action in A549 cells , 2002, British journal of pharmacology.

[25]  Noam Brown,et al.  Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors , 2001, Journal of leukocyte biology.

[26]  R. Huang,et al.  Detection of multiple proteins in an antibody-based protein microarray system. , 2001, Journal of immunological methods.

[27]  P. Kalinski,et al.  Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. , 2001, Blood.

[28]  A. Gabizon.  Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  M. Kuwano,et al.  Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL‐1α , 2000 .

[30]  M. Krstic-Demonacos,et al.  Identification and characterization of glucocorticoid receptors in B16 mouse melanoma cells. , 1999, Endocrine regulations.

[31]  A. Goldberg,et al.  A new model of cancer cachexia: contribution of the ubiquitin-proteasome pathway. , 1999, American journal of physiology. Endocrinology and metabolism.

[32]  G. Burmester,et al.  Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. , 1999, Biochemical pharmacology.

[33]  P. Högger,et al.  Binding kinetics of budesonide to the human glucocorticoid receptor. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  D. Willoughby,et al.  The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[35]  L. Aarden,et al.  Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production , 1995, The Journal of experimental medicine.

[36]  G. Reifferscheid,et al.  Detection of mammalian carcinogens with an immunological DNA synthesis-inhibition test. , 1992, Carcinogenesis.

[37]  J. Junien,et al.  Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. , 1991, Drug Metabolism And Disposition.

[38]  D. Scudiero,et al.  Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. , 1988, Cancer research.

[39]  R. Stockley,et al.  Tissue inhibitor of metalloproteinases and collagenase inhibitory activity in lung secretions from patients with chronic obstructive bronchitis: effect of corticosteroid treatment. , 1986, Thorax.

[40]  C. Chesney,et al.  Effect of platelet-activating factor (PAF) on human platelets. , 1982, Blood.

[41]  Varma Dr.  Anti-inflammatory and ulcerogenic effects and pharmacokinetics of oxyphenbutazone in protein deficient rats. , 1980 .

[42]  S. Fleischer,et al.  Two dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots , 1970, Lipids.

[43]  E. Dubois.  Clinical Potencies of Glucocorticoids: What do we Really Measure? , 2005 .

[44]  S. Johansson,et al.  Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man , 2004, European Journal of Clinical Pharmacology.

[45]  C. Stellato.  Post-transcriptional and nongenomic effects of glucocorticoids. , 2004, Proceedings of the American Thoracic Society.

[46]  J. Wallace.  Humane endpoints and cancer research. , 2000, ILAR journal.

[47]  A. Kolk,et al.  Measurement of antigen specific lymphocyte proliferation using 5-bromo-deoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. , 1991, Journal of immunological methods.

[48]  J. Gustafsson,et al.  Correlation between chemical structure, receptor binding, and biological activity of some novel, highly active, 16 alpha, 17 alpha-acetal-substituted glucocorticoids. , 1984, Molecular pharmacology.

[49]  G. L. Peterson.  [12] Determination of total protein , 1983 .